Kyntra Bio (KYNB) AI Stock Analysis

• Market Cap: $37.30M
• Dividend Yield: N/A
• Average Volume (3M): 30.76K
• Price to Earnings (P/E): 0.2
• Beta (1Y): 1.38
• Revenue Growth: -95.39%
• EPS Growth: N/A
• Country: US
• Employees: 225
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 49.61
• Shares Outstanding: 4,045,445
• 10 Day Avg. Volume: 33,010
• 30 Day Avg. Volume: 30,760
• PEG Ratio: 0.33
• Price to Book (P/B): -5.87
• Price to Sales (P/S): 44.72
• P/FCF Ratio: -9.58
• Enterprise Value/Market Cap: 3.57
• Enterprise Value/Revenue: -1.13
• Enterprise Value/Gross Profit: -1.36
• Enterprise Value/Ebitda: -1.04
• 1Y Price Target: $43.00
• Price Target Upside: 352.63% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: $9.00 ▼(-5.26% Downside)

The score is held back primarily by weak financial performance (declining revenue, negative cash flows, and negative equity). Offsetting positives come from earnings-call updates—cash runway extended into 2028 via the China sale and sharply reduced operating costs—while technicals are mixed and valuation looks optically low but is hard to underwrite given current fundamentals.

Positive Factors

Extended cash runway from China sale

The $220M divestiture materially improves near-term liquidity and reduces immediate solvency pressure, giving management multi-year financing optionality to advance mid/late-stage programs without urgent dilution. This structural cash buffer enables strategic execution of clinical milestones through 2028.

Material operating-cost reductions

An 86% year-over-year cut in operating expenses reflects durable restructuring and a leaner cost base, lowering burn and stretching capital. Sustained lower fixed costs improve resilience to R&D timing and reduce the quantum of future financing required to fund pivotal studies and commercialization prep.

Regulatory progress for roxadustat (Orphan status)

Orphan designation provides regulatory incentives and exclusivity, reducing commercial and development risk for roxadustat in MDS. Combined with proactive Phase 3 planning, this strengthens the drug's long-term commercial profile and makes investment in pivotal development more strategically justifiable.

Negative Factors

Negative stockholders' equity

Persistently negative equity is a structural red flag that constrains financing alternatives, increases creditor and covenant risks, and can force dilutive capital raises. Over the medium term it weakens balance-sheet credibility and limits strategic flexibility for acquisitions or sustained R&D investment.

Persistent negative operating and free cash flow

Continued negative operating and free cash flows indicate the business cannot self-fund development or commercialization. This structural cash burn raises reliance on asset sales, partners, or equity/debt financing, increasing dilution risk and making long-term program funding contingent on external capital access.

Low revenue base and costly upcoming Phase III

A very small revenue base plus ongoing net losses leave the company heavily dependent on financing to fund pivotal Phase III studies. A $50–$60M trial represents a sizable capital requirement relative to current revenue and may force dilutive raises or partnerships, increasing execution risk for the pipeline.

Kyntra Bio Business Overview & Revenue Model

Company Description

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

How the Company Makes Money

FibroGen generates revenue through several key streams. The primary source of income comes from the sale of its approved products, such as roxadustat, in markets where it is commercially available. Additionally, the company may receive milestone payments and royalties from partnerships and collaborations with other pharmaceutical companies that help develop and market its products. Significant partnerships, such as those with larger biopharmaceutical firms, can also provide upfront payments and shared funding for research and development activities. Furthermore, grants and funding from government and non-profit organizations can supplement its revenue, particularly for the advancement of its pipeline projects.

Kyntra Bio Financial Statement Overview

Summary

FibroGen is facing significant financial challenges, with declining revenues, persistent losses, and negative equity. The cash flow issues further exacerbate the situation, limiting the company's ability to invest in growth or cover operational expenses.

Income Statement

FibroGen's income statement reveals significant challenges. The company has experienced negative revenue growth over the past few years, with a sharp decline in total revenue from 2021 to TTM 2025. Despite a high gross profit margin, the net profit margin remains negative, indicating ongoing losses. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and high expenses relative to revenue.

Balance Sheet

The balance sheet shows a concerning financial position with negative stockholders' equity, indicating that liabilities exceed assets. The debt-to-equity ratio is negative due to negative equity, which poses a risk to financial stability. Return on equity is also negative, highlighting the company's inability to generate profit from shareholders' investments.

Cash Flow

FibroGen's cash flow statement indicates severe cash flow issues. Operating cash flow and free cash flow are negative, with a declining trend in free cash flow growth. The operating cash flow to net income ratio is negative, suggesting that the company is not generating sufficient cash from operations to cover its net losses.

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Kyntra Bio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.50
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYNB, the sentiment is Positive. The current price of 9.5 is above the 20-day moving average (MA) of 8.90, above the 50-day MA of 9.21, and above the 200-day MA of 8.83, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 56.88 is Neutral, neither overbought nor oversold. The STOCH value of 82.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KYNB.

Kyntra Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GRCE	58 Neutral	$58.80M	-6.50	-13.15%	―	―	45.97%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KYNB	51 Neutral	$37.30M	0.23	―	―	-95.39%	―
XLO	49 Neutral	$37.98M	―	-908.28%	―	588.40%	61.76%
SNTI	48 Neutral	$28.39M	-0.32	-394.62%	―	―	78.60%
OKUR	42 Neutral	$38.75M	-0.46	-115.64%	―	―	46.20%
GBIO	39 Underperform	$37.13M	-0.59	-80.81%	―	-17.82%	57.32%

Kyntra Bio Corporate Events

FibroGen rebrands as Kyntra Bio, refocuses on oncology

On December 29, 2025, FibroGen filed a certificate of amendment in Delaware to change its corporate name to Kyntra Bio, with the change and related bylaw update becoming effective at 4:30 p.m. Eastern Time on January 7, 2026. The company announced on January 7, 2026, that it is rebranding as Kyntra Bio to reflect its strategic transformation and sharpened focus on oncology and rare disease assets, and its common stock will begin trading on Nasdaq under the new ticker symbol KYNB on January 8, 2026, while retaining the same CUSIP number. Management framed 2025 as a pivotal year marked by the sale of FibroGen China, repayment of its senior secured term loan and extension of its cash runway into 2028, positioning the newly named Kyntra Bio to concentrate on advancing its mid- and late-stage pipeline, including the FG-3246/FG-3180 prostate cancer program and the U.S. development of roxadustat for myelodysplastic syndromes, with key clinical readouts from ongoing trials expected in 2026.

FibroGen Receives $6.4 Million Payment from AstraZeneca

On November 6, 2025, FibroGen, Inc. received a $6.4 million payment from AstraZeneca, fulfilling the first holdback condition of their share purchase agreement. This follows the August 29, 2025, sale of FibroGen’s China operations to AstraZeneca for approximately $220 million, impacting the company’s financials and strategic focus.